{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:35:26Z","timestamp":1793500526181,"version":"4.5.0"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Anti-interferon-\u03b3 autoantibodies (AIGAs) syndrome is a rare, adult-onset immunodeficiency characterized by increased susceptibility to various opportunistic infections. Currently, there are no standardized diagnostic or therapeutic guidelines for AIGAs syndrome, making clinical management challenging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Goals<\/jats:title>\n                    <jats:p>To summarize and synthesize the published literature on the demographic characteristics, infection types, affected organs, treatments, and outcomes of AIGAs syndrome. This review aims to provide a comprehensive summary of current knowledge regarding the epidemiology, pathogenesis, clinical manifestations, diagnosis, and treatment of AIGAs syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, EMBASE for publications in English between January 1, 2004, and March 8, 2025 relating to AIGAs syndrome. Data from eligible studies were extracted and synthesized to summarize demographic characteristics, infection types, affected organs, treatments, and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 149 eligible studies, encompassing 1430 patients (664 males [46.43%], 672 females [46.99%], and 94 with unmentioned gender), were included. Patients frequently presented with two or more opportunistic infections, most commonly non-tuberculous mycobacteria (NTM, 55.69%), Talaromyces marneffei (TM, 26.98%), Salmonella spp. (12.43%), Mycobacterium tuberculosis (9.34%), and varicella-zoster virus (VZV, 9.57%). Multi-organ involvement was common, particularly affecting lymph nodes (70.24%), lungs (58.75%), bones\/joints (38.89%), and skin (45.16%). Clinical outcomes included remission (45.08%), persistent (15.98%), relapse (21.62%), and death (11.68%). In addition to anti-infective therapy, corticosteroids, rituximab, and cyclophosphamide were commonly employed as immunotherapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>AIGAs syndrome is associated with diverse opportunistic infections, particularly NTM, TM, Salmonella, Mycobacterium tuberculosis, and VZV. Multi-organ and multi-system involvement is frequent, with a tendency toward persistent or relapsing disease and associated mortality. Corticosteroids may represent the most promising immunomodulatory therapy in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1615091","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T05:46:48Z","timestamp":1756446408000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Anti-interferon-\u03b3 autoantibodies syndrome and opportunistic infections: systematic literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Ni","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanlin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingliang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqiao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111160","article-title":"Adult-onset immunodeficiency in Thailand and Taiwan","volume":"367","author":"Browne","year":"2012","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00933-2","article-title":"Anti-cytokine autoantibodies: mechanistic insights and disease associations","volume":"24","author":"Cheng","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1629258","article-title":"Blockade Effects of Anti-Interferon- (IFN-) \u03b3 Autoantibodies on IFN-\u03b3-Regulated Antimicrobial Immunity","volume":"2019","author":"Krisnawati","year":"2019","journal-title":"J Immunol Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1086\/380453","article-title":"Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity","volume":"38","author":"D\u00f6ffinger","year":"2004","journal-title":"Clin Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1051673","article-title":"Pathogen spectrum and immunotherapy in patients with anti-IFN-\u03b3 autoantibodies: A multicenter retrospective study and systematic review","volume":"13","author":"Qiu","year":"2022","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2396887","article-title":"Clinical immunological characteristics of anti-interferon-\u03b3 autoantibodies syndrome: a 3 year prospective cohort study","volume":"13","author":"Liang","year":"2024","journal-title":"Emerg Microbes Infect"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad676","article-title":"Efficacy of Bortezomib for Treating Anti-Interferon-Gamma Autoantibody-Associated Adult-Onset Immunodeficiency Syndrome","volume":"78","author":"Angkasekwinai","year":"2024","journal-title":"Clin Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12879-025-10690-3","article-title":"Clinical manifestations in patients with anti-IFN-\u03b3 autoantibodies syndrome and Talaromyces marneffei infection: a prospective cohort study","volume":"25","author":"Liang","year":"2025","journal-title":"BMC Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12890-025-03566-4","article-title":"Clinical characteristics of acquired anti-IFN-\u03b3 autoantibodies in patients infected with non-tuberculous mycobacteria: a prospective cohort study","volume":"25","author":"Liang","year":"2025","journal-title":"BMC Pulm Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-023-00801-5","article-title":"Clinical Characteristics, Course, and Long-Term Outcomes in Patients with Talaromyces marneffei Infection: A 10-Year Retrospective Cohort Study","volume":"12","author":"Yu","year":"2023","journal-title":"Infect Dis Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa035","article-title":"Prospective pilot study of cyclophosphamide as an adjunct treatment in patients with adult-onset immunodeficiency associated with anti-interferon-\u03b3 Autoantibodies","volume":"7","author":"Laisuan","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12865-025-00696-6","article-title":"Serum IgE in the clinical features and disease outcomes of anti-interferon-\u03b3 autoantibodies syndrome","volume":"26","author":"Chen","year":"2025","journal-title":"BMC Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.70962\/jhi.20250002","article-title":"The 2024 update of IUIS phenotypic classification of human inborn errors of immunity","author":"Aziz","year":"2025","journal-title":"J Hum Immun"},{"key":"B14","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1186\/s12879-021-06255-9","article-title":"Clinical findings of Talaromyces marneffei infection among patients with anti-interferon-\u03b3 immunodeficiency: a prospective cohort study","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190502","article-title":"Anti-IFN-\u03b3 autoantibodies underlie disseminated Talaromyces marneffei infections","volume":"217","author":"Guo","year":"2020","journal-title":"J Exp Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/cid\/ciz786","article-title":"Natural History and Evolution of Anti-Interferon-\u03b3 Autoantibody-Associated Immunodeficiency Syndrome in Thailand and the United States","volume":"71","author":"Hong","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-452482","article-title":"Anti-IFN-\u03b3 autoantibodies in adults with disseminated nontuberculous mycobacterial infections are associated with HLA-DRB1*16:02 and HLA-DQB1*05:02 and the reactivation of latent varicella-zoster virus infection","volume":"121","author":"Chi","year":"2013","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10875-020-00762-1","article-title":"Serum Anti-interferon-\u03b3 Autoantibody Titer as a Potential Biomarker of Disseminated Non-tuberculous Mycobacterial Infection","volume":"40","author":"Yoshizawa","year":"2020","journal-title":"J Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/jci19316","article-title":"Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma","volume":"115","author":"Kampmann","year":"2005","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-014-0073-9","article-title":"The first US domestic report of disseminated Mycobacterium avium complex and anti-interferon-\u03b3 autoantibodies","volume":"34","author":"O'Connell","year":"2014","journal-title":"J Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-015-0161-5","article-title":"Late-Onset Disseminated Mycobacterium avium intracellulare Complex Infection (MAC), Cerebral Toxoplasmosis and Salmonella Sepsis in a German Caucasian Patient with Unusual Anti-Interferon-Gamma IgG1 Autoantibodies","volume":"35","author":"Hanitsch","year":"2015","journal-title":"J Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01537-0","article-title":"Characteristics and Outcomes of Anti-interferon Gamma Antibody-Associated Adult Onset Immunodeficiency","volume":"43","author":"Zhang","year":"2023","journal-title":"J Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e76371","DOI":"10.1371\/journal.pone.0076371","article-title":"Autoantibody to interferon-gamma associated with adult-onset immunodeficiency in non-HIV individuals in Northern Thailand","volume":"8","author":"Wongkulab","year":"2013","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1016\/j.cmi.2020.02.030","article-title":"Incorrect diagnoses in patients with neutralizing anti-interferon-gamma-autoantibodies","volume":"26","author":"Wu","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix996","article-title":"Clinical Significance of Interferon-\u03b3 Neutralizing Autoantibodies Against Disseminated Nontuberculous Mycobacterial Disease","volume":"66","author":"Aoki","year":"2018","journal-title":"Clin Infect Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-019-00652-1","article-title":"Juvenile-Onset Immunodeficiency Secondary to Anti-Interferon-Gamma Autoantibodies","volume":"39","author":"Liew","year":"2019","journal-title":"J Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1172\/jci178263","article-title":"Neutralizing IFN-\u03b3 autoantibodies are rare and pathogenic in HLA-DRB1*15:02 or 16:02 individuals","volume":"134","author":"Peel","year":"2024","journal-title":"J Clin Invest"},{"key":"B28","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/nm.4158","article-title":"Identification of a major epitope by anti-interferon-\u03b3 autoantibodies in patients with mycobacterial disease","volume":"22","author":"Lin","year":"2016","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jaci.2015.09.018","article-title":"Anti-IFN-\u03b3 autoantibodies are strongly associated with HLA-DR*15:02\/16:02 and HLA-DQ*05:01\/05:02 across Southeast Asia","volume":"137","author":"Ku","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.cell.2022.12.038","article-title":"Human IRF1 governs macrophagic IFN-\u03b3 immunity to mycobacteria","volume":"186","author":"Rosain","year":"2023","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10875-023-01643-z","article-title":"CXCL9 as a Reliable Biomarker for Discriminating Anti-IFN-\u03b3-Autoantibody-Associated Lymphadenopathy that Mimics Lymphoma","volume":"44","author":"Yuan","year":"2023","journal-title":"J Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20212126","article-title":"Pathogenic autoantibodies to IFN-\u03b3 act through the impedance of receptor assembly and Fc-mediated response","volume":"219","author":"Shih","year":"2022","journal-title":"J Exp Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01210-y","article-title":"Clinicopathological Manifestations and Immune Phenotypes in Adult-Onset Immunodeficiency with Anti-interferon-\u03b3 Autoantibodies","volume":"42","author":"Chen","year":"2022","journal-title":"J Clin Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e0364623","DOI":"10.1128\/spectrum.03646-23","article-title":"Th1 cell immune response in Talaromyces marneffei infection with anti-interferon-\u03b3 autoantibody syndrome","volume":"12","author":"Qiu","year":"2024","journal-title":"Microbiol Spectr"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16870","article-title":"Prevalence and clinical manifestations of cutaneous findings in patients with adult-onset immunodeficiency due to anti-interferon gamma autoantibodies: an eight-year retrospective study","volume":"62","author":"Pattanaprichakul","year":"2023","journal-title":"Int J Dermatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S424212","article-title":"Brain nocardiosis and pulmonary talaromycosis infection in a patient with anti-IFN-\u03b3 Autoantibodies: A case report","volume":"16","author":"Wu","year":"2023","journal-title":"Infect Drug Resist"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1186\/s12879-019-4650-7","article-title":"A case report of Talaromyces marneffei Oro-pharyngo-laryngitis: a rare manifestation of Talaromycosis","volume":"19","author":"Wongkamhla","year":"2019","journal-title":"BMC Infect Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12879-024-09003-x","article-title":"Multiple intracellular pathogen infections with ocular pathologies associated with adult-onset immunodeficiency due to anti-interferon-\u03b3 autoantibodies: a case report","volume":"24","author":"Ning","year":"2024","journal-title":"BMC Infect Dis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58070846","article-title":"Periocular infection of mycobacterium avium complex in a patient with interferon-\u03b3 Autoantibodies: A case report","volume":"58","author":"Lo","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2019.4925","article-title":"Corneal deposits in a patient with anti-interferon-\u03b3 Autoantibody syndrome","volume":"138","author":"Ahmad","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2147\/idr.S337956","article-title":"Retrospective analysis of 10 cases of disseminated nontuberculous mycobacterial disease with osteolytic lesions","volume":"14","author":"Tang","year":"2021","journal-title":"Infect Drug Resist"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1186335","article-title":"Accurate diagnosis of bronchopulmonary Talaromyces marneffei infection in an anti-IFN-\u03b3 autoantibodies positive patient assisted by endobronchial ultrasound-guided TBNA and mNGS: a case report","volume":"13","author":"Chen","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2276310","article-title":"Clinical characteristics of tracheobronchial Talaromyces marneffei infection in non-HIV-infected patients in South China","volume":"55","author":"Pan","year":"2023","journal-title":"Ann Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.05.011","article-title":"Patient ethnicity and causative species determine the manifestations of anti-interferon-gamma autoantibody-associated nontuberculous mycobacterial disease: a review","volume":"88","author":"Hase","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1159\/000528064","article-title":"Reactive neutrophilic dermatoses in adult-onset immunodeficiency due to interferon-gamma autoantibody and their associated Factors","volume":"239","author":"Tungphaisal","year":"2023","journal-title":"Dermatology"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1159\/000347112","article-title":"Reactive and infective dermatoses associated with adult-onset immunodeficiency due to anti-interferon-gamma autoantibody: Sweet's syndrome and beyond","volume":"226","author":"Chan","year":"2013","journal-title":"Dermatology"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000001731","article-title":"Lymphadenopathy associated with neutralizing anti-interferon-gamma autoantibodies could have monoclonal t-cell proliferation indistinguishable from malignant lymphoma and treatable by antibiotics: A clinicopathologic study","volume":"45","author":"Yuan","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000001736","article-title":"Morphologic spectrum of lymphadenopathy in adult-onset immunodeficiency (anti-interferon-\u03b3 Autoantibodies)","volume":"45","author":"Thingujam","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2022.07.015","article-title":"Development of intravascular large B-cell lymphoma during prophylactic antibiotic treatment for anti-interferon-gamma autoantibody syndrome: A case report","volume":"28","author":"Tanigaki","year":"2022","journal-title":"J Infect Chemother"},{"key":"B51","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13223-022-00722-x","article-title":"The unique diagnostic and management challenge of a patient with concomitant anti-interferon-gamma autoantibody associated immunodeficiency syndrome, IgG4-related disease, and treatment refractory, disseminated mycobacterium avium complex infection","volume":"18","author":"Boyle","year":"2022","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e3927","DOI":"10.1097\/md.0000000000003927","article-title":"Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-\u03b3 autoantibodies and disseminated nontuberculous mycobacterial infections","volume":"95","author":"Chi","year":"2016","journal-title":"Med (Baltimore)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.01.021","article-title":"Genetic, immunologic, and clinical features of 830 patients with Mendelian susceptibility to mycobacterial diseases (MSMD): A systematic review","volume":"153","author":"Khavandegar","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60605-9","article-title":"Non-hodgkin lymphoma","volume":"380","author":"Shankland","year":"2012","journal-title":"Lancet"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00202-7","article-title":"Lung disease in primary antibody deficiency","volume":"3","author":"Verma","year":"2015","journal-title":"Lancet Respir Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s43556-025-00244-z","article-title":"Sarcoidosis: molecular mechanisms and therapeutic strategies","volume":"6","author":"Xu","year":"2025","journal-title":"Mol BioMed"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-050219-034449","article-title":"Clinical perspectives on igG4-related disease and its classification","volume":"73","author":"Katz","year":"2022","journal-title":"Annu Rev Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1186\/s12879-024-10217-2","article-title":"Multiple pathogen infections accompanied with ocular pathologies in a patient with high-titer Anti-IFN-\u03b3 autoantibodies: a case report","volume":"24","author":"Wu","year":"2024","journal-title":"BMC Infect Dis"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.06.029","article-title":"Use of QuantiFERON-TB Gold In-tube assay in screening for neutralizing anti-interferon-\u03b3 autoantibodies in patients with disseminated nontuberculous mycobacterial infection","volume":"24","author":"Wu","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01423-1","article-title":"Distinct Lymphocyte Immunophenotyping and Quantitative Anti-Interferon Gamma Autoantibodies in Taiwanese HIV-Negative Patients with Non-Tuberculous Mycobacterial Infections","volume":"43","author":"Lee","year":"2023","journal-title":"J Clin Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-395707","article-title":"Anti-CD20 (rituximab) therapy for anti-IFN-\u03b3 autoantibody-associated nontuberculous mycobacterial infection","volume":"119","author":"Browne","year":"2012","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1163846","article-title":"Case report: Diagnosis of Talaromyces marneffei infection in an HIV-negative patient with septic shock and high-titer anti-interferon gamma autoantibodies by metagenomic next-generation sequencing","volume":"13","author":"Du","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"B63","first-page":"1","article-title":"Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America","volume":"58","author":"Kaplan","year":"2009","journal-title":"MMWR Recomm Rep"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: a comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2000535","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur Respir J"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0212-2021","article-title":"Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments","volume":"31","author":"Kumar","year":"2022","journal-title":"Eur Respir Rev"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e0082423","DOI":"10.1128\/aac.00824-23","article-title":"Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes","volume":"67","author":"El Ghali","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac453","article-title":"Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease","volume":"76","author":"Dedrick","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B69","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12879-019-3771-3","article-title":"Chronic Mycobacterium avium skin and soft tissue infection complicated with scalp osteomyelitis possibly secondary to anti-interferon-\u03b3 autoantibody formation","volume":"19","author":"Xu","year":"2019","journal-title":"BMC Infect Dis"},{"key":"B70","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12879-015-0823-1","article-title":"Treatment outcomes of adjuvant resectional surgery for nontuberculous mycobacterial lung disease","volume":"15","author":"Kang","year":"2015","journal-title":"BMC Infect Dis"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.8366-21","article-title":"Anti-interferon-\u03b3 Antibody-seropositive disseminated nontuberculous mycobacterial infection mimicking POEMS and TAFRO syndromes","volume":"61","author":"Hidekawa","year":"2022","journal-title":"Intern Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.969912","article-title":"Case report: Drug rash with eosinophilia and systemic symptoms syndrome in a patient with anti-interferon-\u03b3 autoantibody-associated immunodeficiency","volume":"13","author":"Nie","year":"2022","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1086","article-title":"Daratumumab (Anti-CD38) for treatment of disseminated nontuberculous mycobacteria in a patient with anti-interferon-\u03b3 Autoantibodies","volume":"72","author":"Ochoa","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B74","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12879-020-04984-x","article-title":"Disseminated Mycobacterium simiae infection in a patient with adult-onset immunodeficiency due to anti-interferon-gamma antibodies - a case report","volume":"20","author":"Keragala","year":"2020","journal-title":"BMC Infect Dis"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2020.09.031","article-title":"Subcutaneous injection of interferon gamma therapy could be useful for anti-IFN-\u03b3 autoantibody associated disseminated nontuberculous mycobacterial infection","volume":"27","author":"Harada","year":"2021","journal-title":"J Infect Chemother"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit809","article-title":"Rituximab as successful adjunct treatment in a patient with disseminated nontuberculous mycobacterial infection due to acquired anti-interferon-\u03b3 autoantibody","volume":"58","author":"Czaja","year":"2014","journal-title":"Clin Infect Dis"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-017-0425-3","article-title":"Rituximab restores IFN-\u03b3-STAT1 function and ameliorates disseminated mycobacterium avium infection in a patient with anti-interferon-\u03b3 autoantibody","volume":"37","author":"Koizumi","year":"2017","journal-title":"J Clin Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"ofac612","DOI":"10.1093\/ofid\/ofac612","article-title":"Intravenous cyclophosphamide therapy for anti-IFN-\u03b3 Autoantibody-associated talaromyces marneffei infection","volume":"9","author":"Zeng","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"B79","doi-asserted-by":"publisher","first-page":"6473629","DOI":"10.1155\/2018\/6473629","article-title":"Intravenous cyclophosphamide therapy for anti-IFN-gamma autoantibody-associated mycobacterium abscessus infection","volume":"2018","author":"Chetchotisakd","year":"2018","journal-title":"J Immunol Res"},{"key":"B80","doi-asserted-by":"publisher","first-page":"e21738","DOI":"10.1097\/md.0000000000021738","article-title":"Non-tuberculous mycobacterial infection and reactive dermatosis associated with adult-onset immunodeficiency due to anti-interferon-gamma autoantibodies: A case report","volume":"99","author":"Liang","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B81","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.1093\/cid\/ciaa129","article-title":"When to Test for Anti-Interferon-\u03b3 Autoantibody","volume":"71","author":"Loh","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e0215581","DOI":"10.1371\/journal.pone.0215581","article-title":"Clinical outcome and laboratory markers for predicting disease activity in patients with disseminated opportunistic infections associated with anti-interferon-\u03b3 autoantibodies","volume":"14","author":"Angkasekwinai","year":"2019","journal-title":"PloS One"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e0005122","DOI":"10.1128\/cmr.00051-22","article-title":"An overlooked and underrated endemic mycosis-talaromycosis and the pathogenic fungus talaromyces marneffei","volume":"36","author":"Wang","year":"2023","journal-title":"Clin Microbiol Rev"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1086\/cid.1997.24.issue-6","article-title":"Case-control study of risk factors for Penicillium marneffei infection in human immunodeficiency virus-infected patients in northern Thailand","volume":"24","author":"Chariyalertsak","year":"1997","journal-title":"Clin Infect Dis"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3201\/eid1702.100718","article-title":"Common reservoirs for Penicillium marneffei infection in humans and rodents, China","volume":"17","author":"Cao","year":"2011","journal-title":"Emerg Infect Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1615091\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T05:46:50Z","timestamp":1756446410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1615091\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":85,"alternative-id":["10.3389\/fimmu.2025.1615091"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1615091","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"article-number":"1615091"}}